Nitnib 12.5mg Capsule: A Breakthrough in Targeted Oncology Therapy
Are you searching for a reliable Nitnib 12.5 mg capsule exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced oncology medications. We cater to major international markets, including the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, providing high-quality pharmaceutical solutions with professional B2B support.
Product Detail: What is Nitnib 12.5 mg?
Nitnib 12.5mg is an oral targeted therapy medication containing Sunitinib Malate. It belongs to the class of Tyrosine Kinase Inhibitors (TKIs) and is widely utilized in modern oncology to treat specific types of tumors that are resistant to traditional chemotherapy.
Primary Therapeutic Indications:
Nitnib 12.5 mg is clinically indicated for:
Renal Cell Carcinoma (RCC): Advanced kidney cancer.
Gastrointestinal Stromal Tumors (GIST): Rare cancers of the digestive tract, especially after other treatments (like imatinib) have failed.
Pancreatic Neuroendocrine Tumors (pNET): Progressive, well-differentiated tumors of the pancreas.
Adjuvant Treatment of RCC: For patients at high risk of recurrent kidney cancer following surgery.
Mechanism of Action: How Nitnib Works:
Nitnib works by inhibiting multiple receptor tyrosine kinases (RTKs) that are overactive in cancer cells. These receptors are responsible for signaling the cell to grow and divide.
Inhibition of Tumor Growth: It blocks receptors like PDGFR and KIT, which are essential for cancer cell survival.
Anti-Angiogenesis: It targets VEGFR (Vascular Endothelial Growth Factor Receptors), preventing the formation of new blood vessels that the tumor needs to receive oxygen and nutrients.
Metastasis Prevention: By disrupting these cellular pathways, Nitnib helps slow down or stop the spread of cancer to other parts of the body.
Dosage and Administration Guidelines:
Cycle for RCC/GIST: Often prescribed as 50 mg (multiple capsules) daily for 4 weeks, followed by a 2-week break.
Continuous Dosing for pNET: Typically 37.5 mg daily without a rest period.
Method: Take the capsule whole with water. It can be taken with or without food, but consistency in timing is key.
Warning: Avoid grapefruit and Seville oranges, as they can significantly alter the drug's metabolism in your system.
Common Side Effects & Monitoring:
While effective, patients may experience:
Fatigue, nausea, or diarrhea.
Hand-Foot Syndrome: Redness or pain on the palms and soles.
High blood pressure (Hypertension).
Changes in taste or skin discoloration.
Monitoring: Regular checks of thyroid function, liver enzymes (LFTs), and blood pressure are essential during therapy.
Why Source Nitnib 12.5 mg from Ernest Oncology?
Quality Assurance: We supply authentic medications manufactured under strict quality controls and GMP compliance.
Bulk Availability: Consistent stock for clinical and hospital requirements.
Global Export Expertise: Seamless shipping and customs handling for the UK, London, USA, Abu Dhabi, Australia, and South Africa.
Competitive B2B Pricing: Specialized rates for international distributors and healthcare providers.
Contact Ernest Oncology—Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD]
Websites: *
www.oncologymedicinesupplier.com Business Type: Exporter | Bulk Supplier | Distributor
WhatsApp: +91 93599 02383
Direct Link:
Chat on WhatsApp
